InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,304.72
(
0.70%
)
US TECH 100
18,318.00
(
0.95%
)
Dow Jones
39,069.59
(
0.01%
)
Brent Oil
81.97
(
0.00%
)
Bitcoin
69,035.67
(
-0.34%
)
Post# of 345846
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

investingdog

Send PM Follow Ignore
Followers 0
Posts 454
Boards Moderated 0
Alias Born 10/07/2012

investingdog

Re: None

Thursday, 02/21/2013 11:35:55 PM

Thursday, February 21, 2013 11:35:55 PM

Post# of 345846
Second line NSCLC Phase IIb trial



from Marketwire - Sep 7, 2012
"The following interim data was presented as part of a late-breaking plenary presentation at the 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology by David Gerber, M.D., Associate Professor of Internal Medicine at the University of Texas Southwestern Medical Center, a principal investigator in the trial."


Does anybody know what is the association between MD David Gerber who presented the interim data and PPHM. Also who did the statistical analysis and what is the normal procedure to unblind the study - is it done by the company or some other FDA approved organization?
Thanks.
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent CDMO News
More CDMO News
InvestorsHub NewsWire

Avant Technologies Engages Wired4Tech to Evaluate the Performance of Next Generation AI Server Technology • AVAI • May 23, 2024 8:00 AM

Branded Legacy, Inc. Unveils Collaboration with Celebrity Tattoo Artist Kat Tat for New Tattoo Aftercare Product • BLEG • May 22, 2024 8:30 AM

"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM

North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM

Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM

Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM

Start posting your company's news
Only $200 per official company press release!